



Potentiometric and Conductometric Determination of Metal Complexes of Tenoxicam in Different Dosage Forms

Awad Ageel Al-Rashdi^{1*}, Ahmed Hosny Naggar², Othman Abd El-Moaty Farghaly²,
Mussa Mohamed Khouda³, Masouda Mohamed Shafter³

¹Chemistry Department, Al-Qunfudah Center for Scientific Research (QCSR), Al-Qunfudah University College, Um Al-Qura University, Saudi Arabia,

²Chemistry Department, Faculty of Science, Al-Azhar University, Assiut Branch, 71524, Assiut, Egypt,

³Chemistry Department, Faculty of Science, Sebha University, Sebha, Libya.

ABSTRACT

Potentiometric and conductometric methods were used to investigate the interaction of tenoxicam (TXM) with 10 metal ions: Fe(III), Cr(III), La(II), Th(IV), Co(II), Mn(II), Pd(II), Ti(II), Sr(II), and Zr(II). The ionization constant of TXM as a ligand and the stability constants of the formed complexes were calculated at 25 ± 0.1 °C in 0.05 M NaNO₃ aqueous solution. Conductometric methods were used to confirm the stoichiometry of the complexes. The metal/ligand ratio was 1:2 or 1:3 depending on the nature of the ligand-metal bonding. The determination of TXM in pure form, and three different dosage forms (tablets, suppository, and injection) was carried out by the potentiometric method, which was simple, precise, rapid, and inexpensive. The quantification of TXM was performed by the well-known standard addition method. The typical limit of quantification was 4.50 mg L⁻¹. The proposed method showed excellent linearity in the range of 0.09–4.66 mg L⁻¹. No interference was observed in the presence of other components that were common in the dosage forms. The recovery of TXM from several tablet dosage formulations ranged from 96.66 to 101.21%.


Key Words: Tenoxicam, Potentiometric, Conductometric, Tablets, Suppository, Injection.

eIJPPR 2018; 8(4):13-22

HOW TO CITE THIS ARTICLE: Awad Ageel Al-Rashdi, Ahmed Hosny Naggar, Othman Abd El-Moaty Farghaly, Mussa Mohamed Khouda, Masouda Mohamed Shafter (2018). "Potentiometric and Conductometric Determination of Metal Complexes of Tenoxicam in Different Dosage Forms", International Journal of Pharmaceutical and Phytopharmacological Research, 8(4), pp.13-22.

INTRODUCTION

Tenoxicam (TXM) is a nonsteroidal anti-inflammatory drug (NSAID) that is a part of the oxycam family, and it can be used as an effective analgesic and antipyretic agent [1, 2]. The chemical formula of TXM is C₁₃H₁₁N₃O₄S₂ (Scheme 1) and the pK_a = 4.50 and 3.73 (Scheme 1)



Scheme 1. Chemical structure of tenoxicam (4-hydroxy-2-methyl-N-(2-pyridinyl)-2H-thieno[2,3-e] [1,2] thiazine-3-carboxamide-1,1-dioxide)

The pharmacological effects of oxycam compounds are linked to the inhibition of cyclooxygenase, which catalyzes the production of cyclic endoperoxides and subsequent prostaglandin formation [3, 4]. The drug is commonly used for the treatment of rheumatic diseases [5, 6] and musculoskeletal and joint disorders [7]. The purity of TXM needs to be monitored because it often contains 2-aminopyridine (2-AP), which is a potential impurity that can be produced synthetically, or as a side product of acid cleavage [8]. According to the British Pharmacopoeia [8], a literature survey showed many different analytical methods for TXM determination, including high-performance liquid chromatography (HPLC) [9-11] and many spectrometric techniques (IR spectrophotometry [12], derivative spectrophotometry [11], flow-injection spectrophotometry [13], spectrofluorimetry [14, 15], and

Corresponding author: Awad Ageel Al-Rashdi

Address: Chemistry Department, Al-Qunfudah Center for Scientific Research (QCSR), Al-Qunfudah University College, Um Al-Qura University, Saudi Arabia.

E-mail: ✉ aarashdi@uqu.edu.sa

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 07 June 2018; **Revised:** 23 July 2018; **Accepted:** 29 August 2018



UV-vis spectrophotometry [16-19]). Different electrochemical methods such as coulometry [20], polarography [21, 22], and voltammetry [23-25] have also been used for TXM determination. However, the application of most of these techniques is usually restricted owing to time consuming processes, complicated operating procedures, high cost, and the need for sophisticated instruments, expensive reagents, and expertise.

Electrochemical methods could overcome the many disadvantages of these techniques. Among various electrochemical methods, the potentiometric method has been extensively used in many branches of solution chemistry because it is one of the most accurate and widely applicable techniques for studying the ionic equilibria of diverse complexes [26]. Potentiometric methods have been used for the study of binary and ternary complexes linked to biological molecules [27-35]. The potentiometric studies of complexes formed between drug compounds and metal ions have helped to elucidate how drug-metal interactions effect drug delivery to the target cells [36, 37]. Additionally, it has been suggested that the presence of metal ions in the composition may enhance the therapeutic action of the drug compounds [38]. Therefore, a large number of medications including TXM are prepared and characterized as metal complexes [39-42]. Such complexes have also been studied using spectrofluorimetric and polarographic techniques [43, 44].

Potentiometric methods have been widely used to quantify compounds in various samples. The Gran plot is a common method widely used to identify the equivalence point and K_a values in potentiometric titration based on linear approximations of the non-linear relationships between the electro-motive potential and the titrant volume [45]. Such a plot has some advantages over the more commonly used sigmoid logarithmic plot. Several applications of the Gran plot have been reported, such as the determination of fluoride by using a specific ion electrode [46], acid rain analysis [47], measuring the levels of strong acid in atmospheric aerosols [48], and the detection of nalidixic acid in pure forms and tablets [49].

Herein, for the first time, in the current study, a potentiometric method was developed for the direct determination of TXM in pure forms, tablets, suppositories, and injections. This method was based on the complexation equilibrium between TXM and different metal ions, and the equilibrium was quantitatively determined for 10 metal ions (Fe (III), Cr (III), La (II), Th (IV), Co (II), Mn (II), Pd (II), Ti (II), Sr (II), and Zr (II)) using Gran plot.

MATERIALS AND METHODS

Apparatus

All pH measurements were obtained with a pH meter (Jenway, UK) fitted with a combined glass electrode, and the total accuracy was 0.01 pH units. Conductometric titration measurements were carried out using a conductivity meter (Model 4320, Jenway, UK) equipped with an immersion cell. The H^+ concentration was used to calibrate the electrode system; therefore, all the equilibrium constants determined in this work were based on the concentration constants. The stoichiometry and stability constants were computed using Excel computer program [43].

Materials

Tenoxicam was purchased from (Sigma-Aldrich, St. Louis, MO, USA), and sodium hydroxide (BDH, Laboratory supplies, Poole, UK). All the other metal ion solutions (as nitrate and chloride salts) were of analytical grade (BDH, UK, Geneva), and used as purchased.

The following pharmaceutical formulations of TXM were analyzed: Mobiflex[®] (tablets containing 20 mg TXM each according to the label, Memphis Chemicals, Egypt), Tenoxicam[®] (suppositories containing 20 mg TXM each according to the label, Dar Al-daoa, Jordan), and Tenoxicam[®] (injections, containing 15 mg TXM per 3-mL ampoule, Micro Labs Limited, India).

Procedures

• Metal Complexes of TXM

The dissociation constant of the ligand (TXM) and the formation constant of its metal complexes at 25 ± 0.1 °C in aqueous ethanol solution were obtained using the potentiometric method adapted from Calvin-Bjerrum's technique as used by Irving and Rossotti [50]. Three sets of solutions were prepared and titrated against 0.05 M carbonate-free NaOH solution (which was standardized against potassium hydrogen phthalate): (a) 0.005 M HNO_3 + 0.045 M $NaNO_3$, (b) Solution (a) + 0.001 M ligand, and (c) Solution (b) + 0.001 M metal nitrate solution. In each case, the total volume was adjusted to 50 mL by adding double-distilled water. The titration was performed at 25 ± 0.1 °C, and different ionic strengths ($I = 0.05, 0.15,$ and 0.25 M $NaNO_3$).

Conductometric titrations were carried out at room temperature by titrating each metal ion solution (25 mL, 1×10^{-3} M) against 1×10^{-2} M TXM solution in 0.5 mL increments. Correction for the dilution effect was performed by multiplying the values of the specific conductance by a factor of $\frac{(25+v)}{25}$, in which v was the volume of titrant added.

Determination of TXM

• TXM in Pure Form

A standard solution of TXM (1×10^{-2} M, 25 mL) was prepared by diluting the stock solution with absolute ethanol and adjusting the ionic strength to 0.5 M with $NaNO_3$. Then, a 15 mL aliquot of this solution was

transferred to a thermostated glass cell (25 ± 1.0 °C). After that, the solution was titrated potentiometrically and conductometrically with a standard solution of NaOH ($I = 0.1$ M).

• **TXM in Tablets**

Ten tablets of Mobiflex®, each containing 20 mg of TXM according to the label, were weighed to calculate their average weight. The tablets were ground into a fine powder and homogenized. A portion of the powder equivalent to 100 mg of TXM was accurately weighed, dissolved in ethyl alcohol, and filtered. The filtrate was then diluted with double-distilled water, and its ionic strength was adjusted to 0.5 M with NaNO₃. Finally, 10 mL of this solution was diluted to 25 mL with double-distilled water, and analyzed using a procedure similar to that described in 3.3.2.1. The quantity of TXM per tablet was calculated from the standard calibration curve.

• **TXM in Suppositories**

Ten Tenoxicam® suppositories, each containing 20 mg of TXM according to the label, were weighed to calculate their average weight. A portion of the mixed suppositories equivalent to 100 mg of TXM was accurately weighed and dissolved in 10 mL of ethanol. The resulting mixture was filtered, and its ionic strength was adjusted to 0.5 M with NaNO₃. Finally, this solution was diluted to 25 mL with double-distilled water, and analyzed using a procedure similar to that described in 3.3.2.1.

• **TXM in Injections**

The contents of 10 Tenoxicam® ampoules, each labeled to contain 15 mg TXM, were mixed thoroughly. A volume equivalent to one ampoule was accurately measured, diluted with double-distilled water, and its ionic strength was adjusted to 0.5 M with NaNO₃. Then, the solution was diluted again with double distilled water to 25 mL and analyzed using the same procedure as described in 3.3.2.1.

RESULT AND DISCUSSION

Formation Constants of TXM Complexes

• **Potentiometric Measurements of TXM with Metal Ions**

Potentiometric and conductometric measurements were carried out on the interaction of TXM with five metal ions: La(II), Ti(II), Sr(II), Fe(III), and Th(IV). In the potentiometric method, the ionization constant of the ligand and stability constant of the formed complex were calculated at 25 ± 0.1 °C in NaNO₃ aqueous solutions with different ionic strengths ($I = 0.05, 0.15, \text{ and } 0.25$ M). The results are shown in Table 1.

Table 1: Protonation constant of TXM and stability constants of metal–TXM complexes at 0.05 M NaNO₃ and 25 ± 0.1 °C

Cation	Log K ₁ (M:L)*	Log K ₂ (M:L)*	Log K ₃ (M:L)*	Ref.
H ⁺	5.00 5.29 (1:1)	Present work 43
Fe (III)	8.70 9.40 (1:2)	6.57 8.90 (1:3)	Present work 43
Th (IV)	7.79 (1:2)	5.97 (1:3)	Present work
La (II)	7.83 (1:2)	6.00 (1:3)	Present work
Ti (II)	7.74 (1:2)	5.81 (1:3)	Present work
Sr (II)	7.81 (1:2)	5.82 (1:3)	Present work

(*) obtained from potentiometric and conductometric methods

• **Proton–TXM Stability Constants**

The potentiometric titration curves of TXM are shown in Fig. 1. Values of $\bar{n}A$ (average number of proton attached to each ligand) were determined according to Irving and Rossotti [50] as shown in Eq. (1):

$$\bar{n}A = Y + \frac{(V_1 - V_2)(N^\circ + E^\circ)}{(V^\circ + V_1)T_c L^\circ} \quad (1)$$

Where V_1 and V_2 are the volumes of alkali required to reach the same pH in a mineral acid (HNO₃) and (HNO₃+TXM) solutions, respectively. $T_c L^\circ$ is the total concentration of the ligand, N° is the normality (concentration) of NaOH solution (0.1 M), and E° is the initial concentration of free HNO₃ in the solution. Calculations of proton–TXM association constants were carried out by plotting $\bar{n}H$ against pH, as shown in Fig. 2. The value of $\text{Log}K_1^H$ (the first proton association constant of TXM) is the pH value corresponding to $\bar{n}H = 0.5$. The obtained pK_a values of TXM-metal complexes (Table 1) were in good agreement with that found in the literature [43].




Fig. 1. Potentiometric titration curves of TXM in $I = 0.5$ M NaNO₃ and at 25 ± 0.1 °C: (a) 0.1 M HNO₃, (b) a + 0.001 M TXM, (c) b + 0.001 M Ti (II), (d) b + 0.001 La (II), (e) b + 0.001 M Sr (II), (f) b + 0.001 M Fe (III), and (g) b + 0.001 M Th (IV)






Fig. 2. Protonation constant curve of TEC in I = 0.5 M NaNO₃ and at 25±0.1 °C

• Formation Constants of Metal–TXM Complexes

The titration curves of the metal–TXM complex solutions (curves *c–g*) differed among themselves and were well separated from that of free ligand solution (curve *b*). Thus, the replacement of H⁺ ion was due to complexation. Equations (2) and (3) were used to calculate the values of \bar{n} (average number of ligand molecules attached per metal ion) and *pL* (free ligand exponent) as shown by Irving and Rossotti [50].

$$\bar{n} = \frac{(V_3 - V_2)(N^\circ + E^\circ)}{(V_0 + V_2)\bar{n}HT_cM^\circ} \quad (2)$$

$$pL = \text{Log} \left[\frac{1 + \beta_1[H^+] + \beta_2[H^+]^2}{(T_c I^\circ - \bar{n}T_c M^\circ)} \times \frac{V_0 + V_3}{V_0} \right] \quad (3)$$

The \bar{n} values were plotted against *pL* to obtain the formation curves of metal complexation equilibria (Fig. 3). From these curves, the stability constants were computed using the half-integral method [50]. For all of the metal–TXM complexes, the formation constants of the second and third complexes were obtained, but those of the first complex were not obtained owing to the chemical nature of TXM and the studied metal ions.





Fig. 3. Representative formation constant curves of binary metal ion-TXM complexes at I = 0.05 M: (a) La (II), (b) Th (IV), (c) Ti (II), (d) Sr (II), and (e) Fe (III)

The protonated amino group (–NH) in TXM was the active site in the complexation process. This site led to the formation of six-membered rings [43]. Furthermore, it was

observed that in TXM, the oxygen of the amide group and the pyridyl nitrogen formed a bond with the metal cation, as shown below (Scheme 2):



Scheme 2: the oxygen of the amide group and the pyridyl nitrogen in TXM

The stability of the different metal–TXM binary complexes in this study could be ordered in a similar way to that reported by Irving and Williams [51] for binary metal–ligand complexes in 0.05 M NaNO₃:



In addition, the effect of the ionic strength on the stability constant of metal–TXM complexes in aqueous solution at 25±0.1 °C was investigated. The ionic strength has been considered as the most important factor in electrolyte solutions, and has had a direct influence on the stability constants of the metal complexes. Five different metal ions, namely Fe (III), Th (IV), Ti (II), Sr (II), and La (II), were complexed with TXM. According to the relationship between *LogK_a* and the ionic strength of these ions shown in Fig. 4, the stability constants of metal–TXM complexes decreased as the ionic strength increased.




Fig. 4. Effect of ionic strength on the stability constants of some metal–TXM complexes

• Conductometric Measurements

The conductometric analysis was based on changes in the electrical conductivity of the solution as a result of complex formation. These changes were directly related to

the number of ions in the complex structures and their movements in the solution. Herein, the conductometric titration curves were used to trace the binary complex formation with different metal ions (Fe (III), Th (IV), La (II), Sr (II), and Ti (II)) at room temperature. The obtained results (Fig. 5) showed that the recorded conductance vs. the volume of titrant was proportional to the mobility of ions in the solution. This might be owing to the neutralization of H^+ during the formation of the M-TXM complex. The slow increase in conductance upon the addition of TXM to the metal ions might be attributed to the formation of the highly charged TXM anions of the relatively weak acid. Two well-defined breaks corresponding to the stoichiometric ratios of 1:2 and 1:3 (M/L) were also evident (Fig. 5). These results were comparable with those obtained by the potentiometric method (Table 1).




Fig. 5. Conductometric titration curves of metal ions (1×10^{-3} M, 25 mL) with 1×10^{-2} M TXM: (a) Fe (III), (b) Th (IV), (c) La (II), (d) Sr (II), and (e) Ti (II)

Species Distribution Diagrams of TXM

The species distribution curve of TXM has been shown in Fig. 6. All the species had a wide protonation range ($pH = 2.6-11.4$). When the pH increased, the protonated ligands lost their protons and converted to the other forms, as shown in Fig.6. The HL species started to form at $pH = 2.6$ and the protonation state decreased up to $pH = 7.8$. The free ligand (L^-) was present from $pH = 3.8$ and reached its maximum concentration at $pH = 11.4$. The data obtained from studying the M-TXM complexes were evaluated using MS Excel® and SPSS® statistical software [43], and the obtained species distribution curves have been shown in Fig. 7. In this figure, the concentrations of various complexes formulated as ML_2 were very small, and depended on the pH and the type of medium.




Fig. 6. Ionization equilibria of TXM at different pH values




Fig. 7. Ionic equilibria of Fe-TXM at different pH values

Potentiometric Determination of Pure TXM

TXM is a weak acid with a dissociation constant $pK_1 = 5.0$ for the amino group. Because $K_1 = 1 \times 10^{-5}$, the titration curve was expected to present a clear inflection at the first point of the equivalence. Accordingly, Fig. 8 shows the potentiometric titration curve with only one inflection point. In our proposed method, the change at the titration end-point was clear, and the produced curve had a satisfactory shape for accurate and reproducible detection of the end-point. Curves (a) and (b) show the first derivative of the combined glass pH-electrode, and curve (c) is the second derivative.




Fig. 8. Typical potentiometric titration curves of pure TXM in tablets (20 mg TXM per tablet): (a) normal titration curve, (b) first derivative, and (c) second derivative

• **Effect of Ionic Strength on the Determination of Pure TXM**

The effect of NaNO₃ ionic strength (0.5–1.5 M) on the potentiometric and conductometric data have been illustrated in Table 2. The best and highest recovery percentages (close to 100%) were obtained in 0.5 M NaNO₃. Thus, an ionic strength of 0.5 M was used for the determination of TXM in pure and dosage forms.

Table 2: Effect of ionic strength on the percentage recovery for pure TXM

Ionic Strength (M)	Added pure (mg)	Found (mg)	Recovery (%)
0.05	15	5.62	37.46
	15	(5.59)	(37.26)
0.1	15	8.43	56.2
	15	(8.41)	(56.07)
0.5	15	15.18	101.2
	15	(15.14)	(100.93)
0.75	15	16.87	112.46
	15	(16.75)	(111.66)
1	15	17.43	116.2
	15	(17.39)	(115.93)
1.5	15	22.49	149.93
	15	(22.44)	(149.6)

Data between parentheses are from the conductometric method

• **Analytical Performance**

Under the optimum conditions (I = 0.5 M NaNO₃), the percentage recoveries were close to 100%. The calculated percentage recoveries were obtained linearly in the ranges of 98.67–99.33 % and 96.43–98.00 % for the potentiometric and conductometric methods; respectively. The corresponding standard deviation (SD) ranges were 0.43–1.21 and 0.4–1.16; respectively, and the 95 % confidence levels were within 0.38–1.06 and 0.33–1.0; respectively for n = 5 replicates (Table 3). These results highlighted the accuracy and precision of the proposed method for TXM determination.

Table 3: Determination of pure TXM using potentiometric and conductometric methods in I = 0.5 M NaNO₃

Added pure (mg)	Found (mg)	Recovery %	SD (n=5)	Confidence (n=5 and α =0.05)
0.	0.0083 (0.0081)	98.81 (96.43)	1.21 (1.16)	1.06 (1.0)
0.015	0.0149 (0.0147)	99.33 (98.0)	0.60 (0.56)	0.52 (0.48)
0.0075	0.0074 (0.099)	98.67 (97.29)	0.88 (0.82)	0.77 (0.70)
0.02	0.0198 (0.0195)	99.0 (97.75)	0.43 (0.40)	0.38 (0.33)

Data in parentheses are from the conductometric method

The detection limit was calculated as 3σ/b, in which σ is the slope of the calibration curve and b is the SD of the three measurements at the lowest point of the calibration line. The quantitative limit was also calculated as 10σ/b. [43] It was evident that TXM could be detected at 4.50 mg mL⁻¹ with a highly linear relationship (R² = 0.9966) and SD = 2.46 for n = 5. TXM was successfully determined using the proposed method in the concentration range of 0.095 to 4.66 mg mL⁻¹ (Fig. 9). In addition to the good analytical performance, the proposed method was easy and simple.




Fig. 9. Linearity range of pure TXM in I = 0.5 M NaNO₃

• **Effect of Interference**

To assess the efficiency and selectivity of the proposed method for TXM determination, a series of sample solutions were prepared containing a fixed amount of TXM, and spiked with common additives and excipients in drugs. The researchers considered the components that often accompanied TXM, such as D(+) lactose monohydrate, sodium chloride, and sodium acetate at concentrations at least 100 times higher than those of TXM. The experiments showed that under the optimum conditions, these common additives had no serious effects on the measurements. Therefore, the proposed method was suitable for highly efficient and selective determination of TXM.

Analytical Application

To assess the applicability of the proposed method for the analysis of pharmaceutical formulations, the recovery test from real TXM samples was carried out for tablet, suppository, and injection formulations. In Fig. 10, curve (a) is the typical potentiometric titration curve with only one inflection point, whereas curves (b) and (c) are the first and second derivatives of (a); respectively.




Fig. 10. Typical potentiometric titration curves of pure Meloxicam in injections (20 mg TXM/3 mL): (a) normal titration curve, (b) first derivative, and (c) second derivative

The results of the conductometric titration of TXM in pure and pharmaceutical preparations are shown in Fig. 11. The obtained data proved that this method could be used successfully for the analysis of such compounds in different dosage forms, and had the advantages of being simple, inexpensive, accurate, and reproducible.




Fig. 11. Typical conductivity curves for the determination of TXM in pure and different dosage forms: (a) Meloxicam tablets (7.5 mg TXM/tablet), (b) Mexicam tablets (15 mg TXM/tablet), (c) Tenoxicam suppositories (20 mg TXM/suppository), (d) pure Tenoxicam (20 mg), and (e) Tenoxicam injection (15 mg TXM/3 mL)

The TXM in tablet, suppository, and injection dosage forms was determined by the proposed method. According to Table 4, the recovery percentage of the two procedures ranged from 96.66 to 101.21 %, with a SD = 0.31–0.78 and confidence limits of 0.28 to 0.68. These results were in good agreement with those determined by the spectrofluorimetric method (100.05± 1.2%) [43].

Although, several methods were described for the determination of TXM with low detection limit, but it still required high cost instruments, reagents and experience. But in the current work, a simple, precise, rapid, low-cost analytical method used for the determination of TXM with excellent recovery was represented as can be shown in Table 3 (in case of TXM determination in pure form) or Table 4 (in case of TXM determination in dosage forms).

Table 4: Recovery data for TXM determination in different dosage forms by potentiometric and conductometric methods

Dosage Forms	Label to content (mg)	Found (mg)	Recovery %	SD (n=5)	Confidence (n=5, α=0.05)
Tenoxicam(Suppositories)	20	19.91 (19.85)	99.55 (99.25)	98.4 (97.75)	19.68 (19.55)
Tenoxicam (Injection)	10	9.97 (9.91)	99.7 (99.1)	101.21 (100)	15.8 (15.0)
Mobiflex® (Tablet)	20	19.95 (19.85)	99.75 (99.25)	97.46 (96.66)	7.31 (7.25)

Data between parentheses are from the conductometric method

CONCLUSION

The complexation reaction between tenoxicam and 10 different metal ions (Fe (III), Cr (III), La (II), Th (IV), Co (II), Mn (II), Pd (II), Ti (II), Sr (II), and Zr (II)) was monitored using either potentiometric or conductometric methods. These methods allowed the identification of the formed complexes, as well as the determination of their stability constants. According to the both methods, the complexes had metal-to-ligand stoichiometric ratios of 1:2 or 1:3. Finally, the distribution of tenoxicamspecies and its metal complexes were found to vary across a wide pH range. Many current methods for the determination of tenoxicam require special instruments, reagents, and expertise, whereas the methods proposed here only involved a simple procedure with a fast response, low cost, and sufficient accuracy for pharmaceutical formulations. The recovery of tenoxicam in various dosage forms ranged from 96.66 to 101.21%, and no interferences were observed.

ACKNOWLEDGEMENTS

This work was supported by the Institute of Research & Consultation Studies at Umm Al-Qura University under Grant 436405042. The authors would like to thank Prof.



Ahmed Alalmi for his assistance in proofreading and editing the manuscript.

REFERENCES

- [1] Al-Obaid, A.M. and Mian, M.S. In: BrittainHG, editors. Analytical Profiles of Drug Substances and Excipients, Academic Press, New York, NY, pp: 431–459.
- [2] Lazer, E.S., Miao, C.K., Cywin, C.L., Sorcek, R., Wong, H.C., Meng, Z., Potocki, I., Hoermann, M., Snow, R.J., Tschantz, M.A., Kelly, T.A., McNeil, D.W., Coutts, S.J., Churchill, L., Graham, A.G., David, E., Grob, P.M., Engel, W., Meier, H. and Trummlitz, G., 1997. Effect of structural modification of enol-carboxamide-type nonsteroidalantiinflammatory drugs on COX-2/COX-1 selectivity. *Journal of Medicinal Chemistry*, 40(6):980–989.
- [3] Woolf, T.F. and Radulovic, L.L., 1989. Oxicams: metabolic disposition in man and animals. *Drug Metabolism Reviews*, 21(2):255–276.
- [4] Heizmann, P., Körner, J. and Zinapold, K., 1986. Determination of tenoxicam in human plasma by high-performance liquid chromatography. *Journal of Chromatography*, 374(1):95–102.
- [5] Gonzalez, J.P. and Todd, P.A., 1987. Tenoxicam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. *Drugs*, 34(3):289–310.
- [6] Vidal, A., Chezal, J.M. and Mounetou, E., 2010. New quaternary ammonium oxicam derivatives: synthesis and in vitro antiosteoarthritis evaluation. *European Journal of Medicinal Chemistry*, 45(1):405–410.
- [7] Starek, M. and Krzek, J., 2009. A review of analytical techniques for determination of oxicams, nimesulide and nabumetone. *Talanta*, 77(3):925–942.
- [8] Van Antwerpen, P. and Nève, J., 2004. In vitro comparative assessment of the scavenging activity against three reactive oxygen species of non-steroidal anti-inflammatory drugs from the oxicam and sulfoanilide families. *European Journal of Pharmacology*, 496(1-3):55–61.
- [9] Múnera-Jaramillo, M.I. and Botero-Garcés, S., 1993. Determination of tenoxicam in plasma by high-performance liquid chromatography. *Journal of Chromatography*, 616(2):349–352.
- [10] Singh, A.K., García, P.L., Gomes, F.P., Kedor-Hackmann, E.R.M. and Santoro, M.I.R.M., 2007. Comparative study on two rapid and sensitive methods for quantitative determination of tenoxicam in tablets. *Brazilian Journal of Pharmaceutical Sciences*, 43(4):615–622.
- [11] El Walily, A.F.M., Blaih, S.M., Barary, M.H., El Sayed, M.A., Abdine, H.H. and El Kersh, A.M., 1997. Simultaneous determination of tenoxicam and 2-aminopyridine using derivative spectrophotometry and high-performance liquid chromatography. *Journal of Pharmaceutical and Biomedical Analysis*, 15(12):1923–1928.
- [12] Atay, O. and Dinçol, F., 1997. Quantitative determination of tenoxicam by infrared spectrophotometry. *Analytical Letters*, 30(9):1675–1684.
- [13] García, M.S., Sánchez-Pedreño, C., Albero, M.I. and Gimenez, M.J., 1999. Flow-injection spectrophotometric methods for the determination of tenoxicam. *Journal of Pharmaceutical and Biomedical Analysis*, 21(4):731–738.
- [14] Barary, M.H., Abdel-Hay, M.H., Sabry, S.M. and Belal, T.S., 2004. Spectrofluorimetric determination of 2-aminopyridine as a potential impurity in piroxicam and tenoxicam within the pharmacopoeial limit. *Journal of Pharmaceutical and Biomedical Analysis*, 34(1):221–226.
- [15] Taha, E.A., Salama, N.N. and Abdel Fattah, L.S., 2002. Stability-indicating methods for determination of meloxicam and tenoxicam in the presence of their degradation products. *Spectroscopy Letters*, 35(4):501–516.
- [16] El-Ries, M.A., 1998. Spectrophotometric determination of piroxicam and tenoxicaminpharmaceutical preparations using uranyl acetate as a chromogenic agent. *Analytical Letters*, 31(5):793–807.
- [17] El-Ries, M.A., Mohamed, G., Khalil, S. and El-Shall, M., 2003. Spectrophotometric and potentiometric determination of piroxicam and tenoxicam in pharmaceutical preparations. *Chemical and Pharmaceutical Bulletin*, 51(1):6–10.
- [18] Mallikarjuna, H., Shivaprasad, K.H., Reddy, K.R.V. and Lokesh, K.S., 2016. Spectrophotometric determination of some nonsteroidal anti-inflammatory drugs by oxidative coupling reaction. *Austin Journal of Analytical and Pharmaceutical Chemistry*, 3(3):1070.
- [19] Amin, A.S., 2002. Spectrophotometric determination of piroxicam and tenoxicam in pharmaceutical formulations using alizarin. *Journal of Pharmaceutical and Biomedical Analysis*, 29(4):729–736.



- [20] Lessigiarska, I., Nankov, A., Bocheva, A., Pajeva, I. and Bijev, A., 2005. 3D-QSAR and preliminary evaluation of anti-inflammatory activity of series of N-pyrrolylcarboxylic acids. *Farmaco*, 60(3):209–218.
- [21] Özaltın, N., 2000. Differential pulse polarographic determination of tenoxicam in pharmaceuticals and added to blood. *AnalyticaChimicaActa*, 406(2):183–189.
- [22] Atkopar, Z. and Tunçel, M., 1996. The polarographic determination of tenoxicam in the pharmaceutical preparations. *Analytical Letters*, 29(13):2383–2397.
- [23] El-Maali, N.A. and Hassan, R.M., 1990. Electrooxidation and determination of the anti-inflammatory drugs piroxicam and tenoxicam at the carbon paste electrode. *Bioelectrochemistry and Bioenergetics*, 24(2):155–163.
- [24] Reguera, C., Ortiz, M.C. and Arcos, M.J., 2002. Differential pulse voltammetric simultaneous determination of four anti-inflammatory drugs by using soft modelling. *Electroanalysis*, 14(24):1699–1706.
- [25] El-Maali, N.A., Vire, J.-C., Patriarche, G.J., Ghandour, M.A. and Christian, G.D., 1990. Square wave and square wave adsorptive stripping voltammetric comparison of the anti-inflammatory drugs piroxicam and tenoxicam. *Analytical Sciences*, 6(2):245–250.
- [26] Rossotti, F.J.C. and Rossotti, H., 1961. *The Determination of Stability Constants and Other Equilibrium Constants in Solution*, McGraw-Hill, New York, NY.
- [27] Amrallah, A.H., Abdalla, N.A. and El-Haty, E.Y., 1998. Mixed ligand complexes of benzimidazole and pyrimidine hydroxyazo dyes with some transition metals and glycine, DL-alanine or DL-leucine. *Talanta*, 46(4):491–500.
- [28] Abdel Gaber, A.A.A., Farghaly, O.A., Ghandour, M.A. and El-Said, H.S., 2000. Potentiometric studies on some cephalosporin complexes. *Monatshheft für Chemie/Chemical Monthly*, 131(10):1031–1038.
- [29] Abdel-Latif, N.M., Abdel-Wadood, H.M. and Farghaly, O.A., 2006. Potentiometric and spectrofluorimetric studies on complexation of levofloxacin with some metal ions. *Egyptian Journal of Analytical Chemistry*, 15:71.
- [30] Ghandour, M.A., Aboul-Kasim, E., Amrallah, A.H., Abdalla, N.A. and Farghaly, O.A., 1999. Potentiometric studies on the complexes of sulfamethazine and sulfathiazole with some metal ions. *Journal of the Indian Chemical Society*, 76:480–482.
- [31] Nishat, N., Hasnain, S., Dhyani, S. and Asma, 2010. Coordination polymers of glutaraldehyde with glycine metal complexes: synthesis, spectral characterization, and their biological evaluation. *Journal of Coordination Chemistry*, 63(21):3859–3870.
- [32] Farghaly, O.A., Mohamed, N.A., Gahlan, A.A. and El-Mottaleb, M.A., 2008. Stability constants and voltammetric determination of some selected drugs. *Indian Journal of Analytical Chemistry*, 7:294.
- [33] Lin, C.E., Lin, W.C., Chen, Y.C. and Wang, S.W., 1997. Migration behavior and selectivity of sulfonamides in capillary electrophoresis. *Journal of Chromatography. A*, 792(1-2):37–47.
- [34] M. Yousef, W.M., Alenezi, K., Naggar, A.H., Hassan, T.M., Bortata, S.Z. and Farghaly, O.A., 2017. Potentiometric and conductometric studies on complexes of folic acid with some metal ions. *International Journal of Electrochemical Science*, 12:1146–1156.
- [35] Daniele, P.G., Zerbinati, O., Zelano, V. and Ostacoli, G., 1991. Thermodynamic and spectroscopic study of copper(II)-glycyl-L-histidylglycine complexes in aqueous solution. *J. Chem. Soc., Dalton Trans*, 24(10):2711–2715.
- [36] Levinson, W., Oppermann, H. and Jackson, J., 1980. Transition series metals and sulfhydryl reagents induce the synthesis of four proteins in eukaryotic cells. *Biochimica et Biophysica Acta*, 606(1):170–180.
- [37] Chan-Stier, C.H., Minkel, D. and Petering, D.H., 1976. Reactions of bis(thiosemicarbazonato) copper(II) complexes with tumor cells and mitochondria. *Bioinorganic Chemistry*, 6(3):203–217.
- [38] Kirschner, S., Wei, Y.K., Francis, D. and Bergman, J.G., 1966. Anticancer and potential antiviral activity of complex inorganic compounds. *Journal of Medicinal Chemistry*, 9(3):369–372.
- [39] Bury, A., Underhill, A.E., Kemp, D.R., O'shea, N.J., Smith, J.P. and Gomm, P.S., 1987. Metal complexes of anti-inflammatory drugs. Part IV. Tenoxicam complexes of manganese(II), iron(III), cobalt(II), nickel(II) and copper(II). *Inorganica Chimica Acta*, 138(1):85–89.
- [40] Defazio, S. and Cini, R., 2003. Synthesis, X-ray structural characterization and solution studies of metal complexes containing the anti-inflammatory drugs meloxicam and tenoxicam. *Polyhedron*, 22(10):1355–1366.
- [41] Moya-Hernández, R., Gómez-Balderas, R., Mederos, A., Domínguez, S., Ramírez-Silva,



- M.T. and Rojas-Hernández, A., 2009. Complex formation of the anti-inflammatory drugs tenoxicam and piroxicam with Fe(III) in methanol and acetone. *Journal of Coordination Chemistry*, 62(1):40–51.
- [42] Mohamed, G.G., El-Sherif, A.A., Saad, M.A., El-Sawy, S.E.A. and Morgan, S.M., 2016. Mixed-ligand complex formation of tenoxicam drug with some transition metal ions in presence of valine: synthesis, characterization, molecular docking, potentiometric and evaluation of the humeral immune response of calves. *Journal of Molecular Liquids*, 223:1311–1332.
- [43] Mohamed, H.A., Wadood, H.M. and Farghaly, O.A., 2002. Potentiometric and spectrofluorimetric studies on complexation of tenoxicam with some metal ions. *Journal of Pharmaceutical and Biomedical Analysis*, 28(5):819–826.
- [44] El-Malli, N.A.E., Vire, J.C., Patriarche, G.J. and Ghandour, M.A., 1989. Copper (II), lead (II) and cadmium (II) complexes with the antiinflammatory drugs piroxicam and tenoxicam. *Analytical Letters*, 22(15):3025–3039.
- [45] Gran, G., 1952. Determination of the equivalence point in potentiometric titrations. Part II. *Analyst*, 77(920):661.
- [46] Barnhard, R.J., 1983. Analytical determination in fluoride ion using Gran's semi-antilog plot. *Journal of Chemical Education*, 60(8):679.
- [47] Ophardt, C.E., 1985. Acid rain analysis by standard addition titration. *Journal of Chemical Education*, 62(3):257–258.
- [48] Ferek, R.J., Lazrus, A.L., Haagenson, P.L. and Winchester, J.W., 1983. Strong and weak acidity of aerosols collected over the northeastern United States. *Environmental Science and Technology*, 17(6):315–324.
- [49] A. Farghaly, O.A., Al-Saidi, H.M., Naggar, A.H. and El-Mabrouk, I.M., 2017. Metal complexes and determination of nalidixic acid by potentiometric and conductometric methods. *International Journal of Electrochemical Science*, 12(10):9865–9881.
- [50] Irving, H. and Rossotti, H.S., 1953. Methods for computing successive stability constants from experimental formation curves. *Journal of the Chemical Society*, 2:3397–3405.
- [51] Irving, H. and Williams, R.J.P., 1948. Order of stability of metal complexes. *Nature*, 162(4123):746–747.